Drug Trial Radar · NCT04659122
A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired Pneumonia
Last checked: Nov 19, 2026Latest source record: Aug 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
5
Actual
Start
Aug 17, 2021
Primary completion
Feb 23, 2023
Study completion Feb 23, 2023
Sponsor
- Lead sponsor
- Airway Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if an investigational drug, AT-100, is safe and tolerated by adults who have severe corona virus disease 2019 (COVID-19) or respiratory failure secondary to severe community acquired pneumonia.
Conditions
- COVID-19
- Undefined
Interventions
AT-100Biological
reconstituted AT-100 for intratracheal administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determining the highest-tolerated & safety-tested AT-100 doseTime frame: From time of initial AT-100 dosing until the end of the dosing period, up to 7 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Airway Therapeutics Investigational Site
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.